A multicenter, phase II, randomized, controlled trial evaluating the efficacy and safety of sunitinib in combination with bevacizumab and paclitaxel in previously untreated patients with metastatic breast cancer

Trial Profile

A multicenter, phase II, randomized, controlled trial evaluating the efficacy and safety of sunitinib in combination with bevacizumab and paclitaxel in previously untreated patients with metastatic breast cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Sunitinib (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms SABRE-B
  • Sponsors Genentech
  • Most Recent Events

    • 23 May 2010 Results published in the Annals of oncology : official journal of the European Society for Medical Oncology (ESMO).
    • 01 Dec 2007 The expected completion date for this trial is now 1 Oct 2010.
    • 28 Mar 2007 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top